Phase III success in progressive multiple sclerosis
This article was originally published in Scrip
The last couple of decades have seen major progress in the treatment of relapsing-remitting multiple sclerosis (RRMS), with a number of drug approvals. In contrast, clinical trials of drug candidates in progressive multiple sclerosis have failed to deliver the same successes. However, a small French biotech company believes it can change all this with its high-dose biotin product.